论文部分内容阅读
目的：研究卵巢癌盆腔引流淋巴结的淋巴细胞，经ＣＤ３单克隆抗体激活后的杀伤细胞ＣＤ３ＡＫ（ＣＤ３ａｃｔｉｖａｔｅｄｋｉｌｅｒｃｅｌｓ）在体外的抗瘤作用。方法：采用卵巢癌病人盆腔引流淋巴结的淋巴细胞，在体外与ＣＤ３单抗和少量ｒＩＬ－２诱导并激活后，在两株人卵巢癌ＨＯ－８９１０、ＨＯ－８９１０ＰＭ细胞系上进行实验研究。将两株细胞各随机分成６组：（１）阴性对照组（Ａ组）：只加新鲜全培养液；（２）低浓度ＣＤ３ＡＫ组（Ｂ组）：５×１０５·Ｌ－１ＣＤ３ＡＫ培养液；（３）中浓度ＣＤ３ＡＫ组（Ｃ组）：１×１０９·Ｌ－１ＣＤ３ＡＫ培养液；（４）高浓度ＣＤ３ＡＫ组（Ｃ组）：２．５×１０９·Ｌ－１ＣＤ３ＡＫ培养液；（５）顺铂阳性对照组（Ｅ组）：含１０ｍｇ·Ｌ－１顺铂培养液；（６）顺铂＋ＣＤ３ＡＫ联合用药组（Ｆ组）：含１０ｍｇ·Ｌ－１顺铂＋１×１０９·Ｌ－１ＣＤ３ＡＫ培养液，分别用ＬＤＨ活性测定、自然杀伤率及台盼蓝活细胞计数法进行了观察。结果：ＣＤ３ＡＫ细胞对卵巢癌细胞有明显的杀伤作用，两株细胞均以中浓度ＣＤ３ＡＫ细胞就显示了较好的细胞毒活性作用（Ｐ＜０．０１），统计学上差异有高度显著性。ＣＤ３ＡＫ细胞与顺铂联合用药时，无论在细胞增?
OBJECTIVE: To study the anti-tumor effect of CD3AK (CD3AK) activated killer CD3AKs activated by CD3 monoclonal antibody in lymph node of ovarian cancer pelvic draining lymph nodes. Methods: Lymphocytes in pelvic draining lymph nodes of ovarian cancer patients were induced and activated in vitro with CD3 monoclonal antibody and a small amount of rIL-2, and then were studied in two human ovarian cancer HO-8910 and HO-8910PM cell lines. The two cells were randomly divided into 6 groups: (1) Negative control group (A group): only fresh whole culture medium; (2) Low concentration CD3AK group (B group): 5 × 105 · L-1CD3AK culture medium; (3) medium concentration CD3AK group (group C): 1 × 109 · L-1CD3AK medium; (4) high concentration CD3AK group (group C): 2.5 × 109 · L-1CD3AK medium; Platinum-positive control group (E group): Cisplatin 10 mg · L -1; (6) Cisplatin plus CD3AK combination group (F group): Incubation with 10 mg · L -1 cisplatin + 1 × 109 · L -1 CD3AK Liquid, were measured by LDH activity, natural killer rate and trypan blue survival cell counting method were observed. Results: CD3AK cells had a significant killing effect on ovarian cancer cells. Both of the two cells showed good cytotoxic activity with medium concentration of CD3AK cells (P <0.01), and the difference was statistically significant. CD3AK cells and cisplatin combination therapy, both in the cell proliferation?